Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer

Author(s): R. E. Nunez-Anita, M. Cajero-Juarez, C. Aceves.

Journal Name: Current Cancer Drug Targets

Volume 11 , Issue 7 , 2011

Become EABM
Become Reviewer

Abstract:

Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription factors. Three subtypes -- PPAR alpha, PPAR beta, and PPAR gamma -- have been identified and are differentially expressed in tissues. Originally, they were described as molecular regulators of lipid metabolism; recently, it has been shown that they are also involved in regulating the cell cycle and apoptosis in both normal and tumoral cells. In fact, some synthetic PPAR ligands are used to treat dyslipidemia, metabolic diseases, and type 2 diabetes. Here, we review the role of PPAR gamma (PPARγ) in tumor initiation and progression, emphasizing the relationship between this isoform and the cellular and molecular mechanisms involved in the antineoplastic effect of iodine on mammary cancer.

Keywords: Antineoplastic, apoptosis, iodine, iodolactone, mammary cancer,, peroxisome proliferator-activated receptor (PPAR), sodium-iodide symporter, prostate specific antigen, thiazolinidinedione, ciglitazone, Peroxisome proliferator response element, non-steroidal anti-inflammatory drugs

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 11
ISSUE: 7
Year: 2011
Page: [775 - 786]
Pages: 12
DOI: 10.2174/156800911796798931
Price: $65

Article Metrics

PDF: 5